Monjuvi shows real-world effectiveness in relapsed/refractory DLBCL, with 11.3 months PFS and 24.8 months OS. Second-line Monjuvi treatment yields higher ORR (78.5%) compared to third-line (62.8%).

A new commercial real estate asset class doesn’t emerge every day. However, that’s exactly what unfolded with the rise of real estate underlying cell site tower infrastructure. As pioneers in the ...

Cell migration is a multistep process essential to various physiological functions, including immune cell movement and embryonic development, as well as pathological conditions like tumor metastasis.

insights from industryYavuz ÇelikGlobal Product ManagerHamilton Bonaduz AG In this interview, News Medical speaks with Yavuz Çelik, Global Product Manager at Hamilton, about how real-time cell density ...

New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma FRANKLIN LAKES, N.J., May 13, 2025 /PRNewswire/ -- BD (Becton, ...

A research team of the University Medical Center Mainz has succeeded in observing for the first time how G protein-coupled receptors in living cells actually respond to activating substances. The ...

In this innovation spotlight, Tia Harmon, technical science liaison, CGT for PHC Corporation of North America (PHCNA), discusses the key challenges in CGT manufacturing and how in-line monitoring ...

FRANKLIN LAKES, N.J., May 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the global commercial launch of the world's ...